Citigroup Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $31
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Joanne Wuensch has maintained a Neutral rating on Tandem Diabetes Care (NASDAQ:TNDM) and lowered the price target from $33 to $31.

August 21, 2023 | 11:34 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Citigroup has maintained a Neutral rating on Tandem Diabetes Care and lowered the price target from $33 to $31.
The lowering of the price target by Citigroup could potentially lead to a negative sentiment among investors, which may put downward pressure on TNDM's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100